Search
Novo Nordisk Speeds Up FDA Approval Process for Oral GLP-1 Drug: A Strategic Maneuver Amid Eli Lilly's Competitive Pressure
2025-04-23 /
Read about 0 minute
Author：小编
Novo Nordisk has announced the submission of a marketing application to the U.S. Food and Drug Administration (FDA) for an oral version of its GLP-1 weight loss medication. This novel formulation represents an oral alternative to the injectable weight loss drug Wegovy (semaglutide). Remarkably, in clinical trials, patients receiving the highest dose achieved a 15% reduction in body weight over a period of 64 weeks.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
